The purpose of this study is to evaluate the effect of varenicline on rectal sensation, based on ascending method of limits and on graded rapid phasic distensions in participants with non-constipation IBS and chronic abdominal pain.

Start Date08 May 2025

Sponsor / Collaborator

Mayo Clinic

NCT06883162

/ Not yet recruitingPhase 3IIT

Randomized Controlled Trial of Varenicline to Treat Tobacco and Cannabis Co-Use (RECLAIM)

The purpose of the RECLAIM study is to evaluate the effectiveness of varenicline (sometimes known as Chantix) compared to placebo (an inactive substance) for the treatment of cigarettes and cannabis (marijuana). Varenicline is not FDA approved for the combination treatment of cigarette abstinence and cannabis reduction or abstinence. All participants will also receive counseling and access to online treatment modules during a quit attempt for cigarettes and a reduction attempt for cannabis. This study is being conducted by the Medical University of South Carolina. All procedures are conducted remotely and there is no in-person visits are needed.
To qualify, participants must be 18 or older, live in South Carolina, use cigarettes and cannabis, and are interested in quitting cigarettes and reducing cannabis.

Start Date22 Apr 2025

Sponsor / Collaborator

The Medical University of South Carolina

[+1]

NCT06679374

/ RecruitingPhase 2IIT

Reducing Falls With Varenicline in Hypocholinergic Parkinson Disease

This trial aims to test whether one year of Varenicline, when compared to placebo, can reduce fall risk and show improvement in the ability to multitask while walking.
Participants that are eligible after screening for the study will be randomized to receive Varenicline or placebo. Along with the study medication participants will have visits (over the phone and in person), various tests and imaging, questionnaires, and laboratory collections.

Start Date09 Apr 2025

Sponsor / Collaborator

University of Michigan

[+1]

100 Clinical Results associated with Varenicline Tartrate

100 Translational Medicine associated with Varenicline Tartrate

100 Patents (Medical) associated with Varenicline Tartrate

2,608

Literatures (Medical) associated with Varenicline Tartrate

01 May 2025·Ophthalmology and Therapy

Varenicline Nasal Spray for the Treatment of Dry Eye Disease Following Corneal Collagen Crosslinking

Article

Author: Swan, Russell J ; Whitt, Travis ; Ferguson, Tanner J ; Durgan, David

INTRODUCTION:

To evaluate the safety and effectiveness of a varenicline solution nasal spray 0.03 mg (VNS) in reducing signs and symptoms of dry eye disease following corneal collagen cross-linking (CXL).

METHODS:

Subjects undergoing CXL were randomized to VNS (study) or vehicle (control) twice daily and initiated treatment with VNS 28 days prior to the procedure with continued use for 28 days following the procedure. After starting treatment, subjects were seen on the day of surgery and postoperatively at days 2, 3, 4, 7 and 28. The primary outcome measure was the change in the National Eye Institute Visual Function Questionnaire (NEI-VFQ)-25, a dry eye questionnaire, from baseline to day 28. The second primary outcome measure was the mean area change of corneal epithelial healing following the CXL procedure. The secondary outcome measures for this study were the eye dryness score (EDS), degree of fluorescein staining and supplemental artificial tear usage.

RESULTS:

Twelve subjects were enrolled in the study group and eight in the control group. At day 28, the NEI-VFQ-25 questionnaire demonstrated an improvement from baseline in the study group and a reduction in the control group, but the between-group comparison was not statistically significant (p > 0.05). There was a directional trend toward faster mean change of epithelial healing in the study group, but the difference was not statistically significant at any time point. There were four total adverse events, all of which were mild in nature and resolved without sequelae.

CONCLUSIONS:

VNS is an attractive treatment option for patients following CXL. Patients hoping to avoid punctal occlusion or additional use of topical medications following a procedure such as CXL may be well suited for a neurostimulator treatment option like VNS that spares the ocular surface.

TRIAL REGISTRATION:

Registered with clinicaltrials.gov (NCT05136924).

22 Apr 2025·NICOTINE & TOBACCO RESEARCH

Can We Predict Who Will Experience Adverse Events While Using Smoking Cessation Pharmacotherapy? A Secondary Analysis of the EAGLES Clinical Trial

Article

Author: Tomko, Rachel L ; Dahne, Jennifer R ; Wolf, Bethany J ; Gray, Kevin M ; Hashemi, Daniel

Abstract:

Introduction:

Concerns about potential side effects remain a barrier to uptake of Food and Drug Administration-approved smoking cessation pharmacotherapy (ie, varenicline, bupropion, nicotine replacement therapy [NRT]). However, use of pharmacotherapy can double the odds of successful quitting. Knowledge of an individual’s likelihood of side effects while taking smoking cessation pharmacotherapy could influence treatment planning discussions and monitoring.

Methods:

We conducted a secondary, post hoc analysis to predict an individual’s likelihood of adverse events (AEs) using the Evaluating Adverse Events in a Global Smoking Cessation Study data from 4209 adults in the United States who smoked. Participants were randomized to receive 12 weeks of treatment with varenicline, bupropion, NRT patch, or placebo. Our models predicted the likelihood of moderate to severe psychiatric and nonpsychiatric AEs during treatment.

Results:

Using pretreatment demographic and clinical data, multivariable logistic regression models yielded acceptable areas under the receiver operating characteristic curve for an individual’s likelihood of moderate to severe (1) psychiatric AEs for bupropion and NRT and (2) nonpsychiatric AEs for varenicline and bupropion. Once we adjusted for demographic and baseline characteristics, medication was not associated with psychiatric AEs. Varenicline differed from placebo with regards to nonpsychiatric AEs.

Conclusions:

It is possible to predict person-specific likelihood of moderate to severe psychiatric and nonpsychiatric AEs during smoking cessation treatment, though the probability of psychiatric AEs did not differ by medication. Future work should consider factors related to implementation in clinical settings, including determining whether lower burden assessment protocols can be equally accurate for AE prediction.

Implications:

Using data from a large dataset people who smoke in the United States, it is possible to predict an individual’s likelihood of psychiatric and nonpsychiatric AEs during smoking cessation treatment prior to initiating treatment. These predictive models provide a starting point for future work addressing how best to modify and integrate such clinical decision support algorithms into treatment for smoking cessation.

01 Apr 2025·NEUROCHEMICAL RESEARCH

Varenicline Attenuates Memory Impairment in Amyloid-Beta-Induced Rat Model of Alzheimer’s Disease

Article

Author: Ghaderi, Pedram ; Sadigh-Eteghad, Saeed ; Hajihosseinlou, Fatemeh ; Farajdokht, Fereshteh ; Majdi, Alireza ; Vatandoust, Seyed Mehdi ; Athari, Seyed Zanyar ; Mahmoudi, Javad ; Kazmi, Sareh

Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder characterized by cognitive decline. Despite extensive research, therapeutic options remain limited. Varenicline, an α₄β₂ nicotinic acetylcholine receptor agonist, shows promise in enhancing cognitive function. This study aimed to evaluate varenicline's effect on memory and hippocampal activity in rat model of AD. Forty-eight adult male Wistar rats were randomly assigned to control, sham, AD, and varenicline (0.1, 1, and 3 mg/kg/po for 14 days) groups. AD was induced by intracerebroventricular (i.c.v.) injection of 4 µl amyloid-beta (Aβ)_1-42 (1 µg/µl). Spatial learning and memory, hippocampal synaptic function, and CA1 electrophysiological activity were evaluated using appropriate methods. Barnes maze and T-maze behavioral tests revealed that varenicline, particularly at 1 mg/kg, significantly improved spatial memory compared to the AD group. Western blot analysis showed varenicline's ability to upregulate synaptic proteins PSD-95, synaptophysin, and GAP-43 in the hippocampus, with the most significant effects observed at 1 mg/kg. Electrophysiological recordings demonstrated that varenicline at 1 mg/kg enhanced hippocampal long-term potentiation (LTP), indicating improved synaptic plasticity. Single-unit recordings showed an increase in spike count with varenicline administration. These findings suggest that varenicline, particularly at 1 mg/kg, ameliorates memory deficits in AD rats possibly through modulation of synaptic proteins and enhancement of hippocampal LTP and electrical activity. Further investigations are warranted to elucidate varenicline's precise mechanisms of action in alleviating AD-induced cognitive deficits and its potential as a therapeutic intervention for AD-related cognitive impairment.

110

News (Medical) associated with Varenicline Tartrate

21 Apr 2025

·ir.achievelifesciences.com

Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine

ORCA-3 Demonstrated a Significant Increase in Quitting and Reduction in Nicotine Cravings for Cytisinicline-Treated Participants Compared to Placebo Cytisinicline New Drug Application (NDA) Submission to FDA Planned for June 2025 SEATTLE and VANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that complete trial results from its ORCA-3 were published in the Journal of the American Medical Association (JAMA) Internal Medicine. ORCA-3 was the second randomized, placebo-controlled Phase 3 clinical trial evaluating cytisinicline for smoking cessation in 792 U.S. adults. The authors concluded that ORCA-3 reaffirms cytisinicline’s efficacy and tolerability for smoking cessation in adult smokers at both 6- and 12-week treatment durations, including reduction in nicotine cravings and extended cessation benefits through 24 weeks. In addition to previously reported topline results announced in May 2023, the published completed trial results provided further evidence of cytisinicline’s highly targeted effect on treating nicotine dependence by binding to specific nicotine receptors. These consistent results, now published from two large, randomized Phase 3 trials, demonstrated that cytisinicline significantly reduced nicotine cravings and increased the likelihood of quitting smoking. In clinical trials, cytisinicline was well tolerated, which is thought to be due to limited other off-target binding effects that can result in side effects known to be associated with currently available treatments. Similar to the first Phase 3 trial, ORCA-3 participants had an average age of 53 years, smoked a median of 20 cigarettes per day at baseline, and had a median smoking history of 36 years with four prior quit attempts. “Most people who smoke want to quit and it often takes multiple attempts to do so successfully. Our trial participants were no exception and had multiple previous quit attempts, although less than half had previously tried varenicline, possibly due to its well-known adverse event profile,” said Cindy Jacobs, MD, PhD, President and Chief Medical Officer of Achieve Life Sciences. “Cytisinicline is very selective in targeting only nicotine receptors and has shown limited binding to other off-target receptors that can cause side effects, like nausea and gastrointestinal disturbances. We believe this leads to a highly tolerable treatment with cytisinicline, as demonstrated in our clinical trial program.” Results from the ORCA-3 study show that cytisinicline significantly increased the odds of smoking cessation compared to placebo. Cytisinicline also reduced nicotine craving which led to decreased nicotine intake, even among those who continued smoking, as evidenced by both lower craving scores and reduced cotinine levels, a well-known metabolite of nicotine. “More deaths each year in the U.S. are attributed to cigarette smoking than to any other preventable cause, and our current smoking cessation treatment options are limited,” said Nancy Rigotti, MD, Professor of Medicine at Harvard Medical School, Director of Tobacco Research and Treatment Center, Massachusetts General Hospital, and ORCA Program Investigator. “The study findings published today suggest that cytisinicline, if approved by the FDA, could help many smokers to quit and reduce the smoking-related risks to their health.” Achieve plans to submit the cytisinicline New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in June 2025. About ORCA-3 The Phase 3 ORCA-3 trial evaluated 792 adults who smoked cigarettes daily and was conducted at 20 clinical trial locations in the U.S. The trial was initiated in January 2022 and completed enrollment in September 2022, with topline results reported in May 2023. ORCA-3 participants received 3mg cytisinicline dosed 3 times daily for either 6 or 12 weeks and were monitored through 24 weeks post randomization. The trial was blinded, placebo-controlled, and all subjects received behavioral support for the duration of the trial. The primary endpoint was biochemically verified continuous abstinence during the last four weeks of treatment. Secondary outcome measures assessed continued abstinence rates through 6 months from the start of study treatment. The full manuscript is published in Journal of the American Medical Association (JAMA) Internal Medicine. About Achieve Life Sciences, Inc. Achieve Life Sciences is a late-stage specialty pharmaceutical company committed to addressing the global smoking health and nicotine dependence epidemic through the development and commercialization of cytisinicline. The company has successfully completed two Phase 3 studies with cytisinicline for smoking cessation and one Phase 2 study with cytisinicline in vaping cessation. The company has fully enrolled its ongoing open-label safety study with cytisinicline and plans to submit its new drug application for smoking cessation in June 2025. Achieve has also conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. About Cytisinicline There are approximately 29 million adults who smoke combustible cigarettes.1 Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the United States annually.2,3 More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke.3 In addition, there are over 11 million adults in the United States who use e-cigarettes, also known as vaping.4 In 2024, approximately 1.6 million middle and high school students in the United States reported using e-cigarettes.5 There are no FDA-approved treatments indicated specifically as an aid to nicotine e-cigarette cessation. Cytisinicline has been granted Breakthrough Therapy designation by the FDA to address this critical need. Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine addiction for smoking and e-cigarette cessation by interacting with nicotine receptors in the brain, reducing the severity of nicotine craving symptoms, and reducing the reward and satisfaction associated with nicotine products. Cytisinicline is an investigational product candidate being developed for the treatment of nicotine addiction and has not been approved by the Food and Drug Administration for any indication in the United States. Forward Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the timing and nature of cytisinicline clinical development and regulatory review and approval, data results and commercialization activities, the potential market size for cytisinicline, the potential benefits, efficacy, safety and tolerability of cytisinicline, the development and effectiveness of new treatments, and the successful commercialization of cytisinicline. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the risk that cytisinicline may not demonstrate the hypothesized or expected benefits; the risk that Achieve may not be able to obtain additional financing to fund the development and commercialization of cytisinicline; the risk that cytisinicline will not receive regulatory approval in a timely manner or at all, or be successfully commercialized; the risk that new developments in the smoking and vaping cessation landscapes require changes in business strategy or clinical development plans; the risk that Achieve’s intellectual property may not be adequately protected; general business and economic conditions; risks related to the impact on our business of macroeconomic and geopolitical conditions, including fluctuating inflation, interest and tariff rates, volatility in the debt and equity markets, actual or perceived instability in the global banking system, global health crises and pandemics and geopolitical conflict and the other factors described in the risk factors set forth in Achieve’s filings with the Securities and Exchange Commission from time to time, including Achieve’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable. Achieve Contact Nicole Jones ir@achievelifesciences.com 425-686-1510 References 1VanFrank B, Malarcher A, Cornelius ME, Schecter A, Jamal A, Tynan M. Adult Smoking Cessation — United States, 2022. MMWR Morb Mortal Wkly Rep 2024;73:633–641. 2World Health Organization. WHO Report on the Global Tobacco Epidemic, 2019. Geneva: World Health Organization, 2017. 3U.S. Department of Health and Human Services. The Health Consequences of Smoking – 50 Years of Progress. A Report of the Surgeon General, 2014. 4Cornelius ME, Loretan CG, Jamal A, et al. Tobacco Product Use Among Adults – United States, 2021. MMWR Morb Mortal Wkly Rep 2023;72:475–483. 5Jamal A, Park-Lee E, Birdsey J, et al. Tobacco Product Use Among Middle and High School Students — National Youth Tobacco Survey, United States, 2024. MMWR Morb Mortal Wkly Rep 2024;73:917–924. Released April 21, 2025

Phase 3Clinical ResultPhase 2NDABreakthrough Therapy

10 Jan 2025

·www.drugs.com

The Best Ways to Quit Vaping - Drugs.com MedNews

FRIDAY, Jan. 10, 2025 -- Text-based support programs are one of the best ways to help young people quit vaping, a new evidence review says. These texts offer motivational messages and tips for quitting vaping. “I think it’s clear that this approach helps young people,” senior researcher Jamie Hartmann-Boyce , an assistant professor of health policy and management at the University of Massachusetts Amherst, said in a news release from the college. “The question is, is it going to help other populations?” The review also found evidence that the quit-smoking drug varenicline might also help folks quit vaping. However, there still aren’t enough studies available to point to any concrete, tried-and-true methods for quitting vaping, researchers said in a study published Jan. 8 in the Cochrane Database of Systematic Reviews .. “This is an area of research that is in its infancy, but is growing rapidly and organically from people who vape asking about help to quit vaping,” Hartmann-Boyce said. Previous reviews have found that e-cigarettes can help people quit smoking more effectively than other nicotine replacements like patches, gums or lozenges, researchers said. But what to do when one wants to quit vaping, which also involves nicotine addiction? “We also know that people who use vaping as a way to transition away from smoking are often keen to know how they can safely transition away from vaping without relapsing to smoking, which is really important,” Hartmann-Boyce said. For the review, researchers identified nine previous clinical trials involving more than 5,000 participants. They found strong evidence for the effectiveness of text-based quitting support, and some evidence supporting varenicline. Varenicline works by stimulating nicotine receptors in the brain, thus reducing nicotine cravings and withdrawal symptoms. Evidence regarding other nicotine replacement therapies to help quit vaping indicated some possible benefit, but were too imprecise and at risk of bias to make any conclusion, researchers said. Armed with this review, “healthcare professionals now have initial evidence for specific approaches they can recommend, particularly for younger people wanting to quit vaping,” co-lead author Alisa Butler , a postdoctoral researcher with the University of Oxford, said in a news release. “However, we urgently need more research to explore these and other approaches.” Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

12 Nov 2024

·www.pharmaceutical-technology.com

NHS launches “game-changer” and lifesaving anti-smoking pill

The NHS spends £2.5bn each year on smoking- related illnesses and hospitalisations. Image credit: Shutterstock/ Gorynvd. As the UK Government presses ahead with laws to create a smoke-free generation, tens of thousands of smokers will now benefit from an improved version of a smoking cessation pill thanks to a roll-out by the National Health Service (NHS). Varenicline will be offered to around 85,000 smokers in England to help them kick the habit alongside behavioural support, as per a 12 November press release. NHS England states that the tablet is as effective as vapes in helping people stop smoking, and even better than nicotine-replacement gum or patches. Around a quarter of those taking varenicline in tandem with behavioural support stop smoking for at least six months, the health service said. Varenicline helps block cravings for nicotine, the addictive chemical found in tobacco products. The drug also helps with withdrawal symptoms such as irritability and sleep issues. The smoking cessation pill was previously known under the brand name Champix, made by Pfizer since 2006. Champix was withdrawn in 2021 as a precaution after an impurity was discovered, with a new generic version approved by the Medicines Health and Regulatory Authority (MHRA) this month. Pharmaceutical company Teva UK will manufacture the drug for the NHS. A decline in smoking rates over the past couple of decades means that only 11.6% of adults in England still smoke – about 6 million people. There were nevertheless approximately 74,600 deaths in the UK linked to smoking in 2019, accounting for around 15% of all deaths that year. Varenicline’s use could help avoid 1,890 smoking-related deaths each year, according to research carried out by University College London. In addition, previous data on Champix showed that £1.65 was saved in healthcare costs for every £1 spent on the drug. NHS England expects the cost-benefit ratio to be even better with the cheaper generic version. NHS chief executive, Amanda Pritchard says: “This simple daily pill could be a game-changer for people who want to quit smoking and is another vital step in shifting our NHS further towards prevention.” The UK Government introduced the Tobacco and Vapes Bill in Parliament last week as it looks to curb the £2.5bn spent each year on the NHS treating health issues caused by smoking. The new set of laws will prevent anyone who was born on or after 1 January 2009 from buying tobacco, which effectively raises the legal age for buying cigarettes in England by one year every year. “Alongside supporting the Government’s ambition to create the first smoke-free generation, we are giving current smokers the tools they need to quit – with proven treatment options like this, alongside specialist care, helping to save thousands of lives and the NHS millions of pounds in treatment costs,” Pritchard adds. The National Institute for Health and Care Excellence ( Nice ) is currently reviewing a second drug called cytisine that could also help in the fight against smoking – this compound works in a similar way to varenicline. Semaglutide, marketed as weight loss and diabetes drugs Wegovy and Ozempic respectively, has also been touted as a potential helper, with a study showing patients on the medication were less likely to take smoking cessation treatment .

Drug Approval

100 Deals associated with Varenicline Tartrate

External Link

KEGG	Wiki	ATC	Drug Bank
D06282	Varenicline Tartrate	N07BA03	DB01273

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Xerophthalmia	Macao	Corxel Pharmaceuticals (Shanghai) Co., Ltd	01 Feb 2023
Dry Eye Syndromes	United States	Oyster Point Pharma, Inc.	15 Oct 2021
Tobacco Use Disorder	Japan	Pfizer Japan, Inc.	25 Jan 2008
Smoking Cessation	United States	PF Prism CV	10 May 2006

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Harm Reduction	Phase 3	United States	Rose Research Center LLCStartup	19 Nov 2019
Lung Cancer	Phase 3	United States	Pfizer Inc.	29 Sep 2017
Nicotine Dependence	Phase 3	United States	Pfizer Inc.	01 May 2010
HIV Infections	Phase 3	France	Pfizer Inc.	01 Oct 2009
Acral Lentiginous Malignant Melanoma	Phase 3	Denmark	Pfizer Inc.	01 Sep 2009
Friedreich Ataxia	Phase 3	United States	Pfizer Inc.	01 May 2009
Schizoaffective disorder	Phase 3	United States	Pfizer Inc.	01 May 2008
Schizoaffective disorder	Phase 3	Canada	Pfizer Inc.	01 May 2008
Schizophrenia	Phase 3	United States	Pfizer Inc.	01 May 2008
Schizophrenia	Phase 3	Canada	Pfizer Inc.	01 May 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05367492 (ViVA, CTgov)	Phase 4	Nicotine Dependence	261	This Is Quitting	wgiditnack = xtcxiavjen xmasayrpnv (wyhwosusuv, ynvgamlhys - uorexemrrd) View more	-	27 Apr 2025
NCT05541497 (CTgov)	Phase 2	Smoking Cessation	40	Varenicline Tartrate (Varenicline + Self-Change Pamphlet)	cnwtpjuvka = acxwkeoqwt lmyslnqcqa (ebrjbqhuju, cihkpftinv - aukxbmjdsa) View more	-	02 Dec 2024
				Placebo (Placebo + Self-Change Pamphlet)	cnwtpjuvka = gbkaehfern lmyslnqcqa (ebrjbqhuju, kbzauhmfzg - hwaokitrmt) View more
NCT05700422 (CTgov)	Phase 4	Sjogren's Syndrome	39	Varenicline Nasal Spray	dsuslecsum(llvxthbqeu) = vzbnqjdyxa pasvgismdw (hchwmpemce, tidqmkgaiu - viviumfxez) View more	-	05 Nov 2024
NCT04083144 (CTgov)	Not Applicable	Smoking Cessation \| Tobacco Use Disorder	50	Deep Repetitive Transcranial Magnetic Stimulation (Active)+Varenicline (Deep rTMS Active + Varenicline)	utsoejzrtg(ksgajcezoo) = cuockcwwop ouynhwwsyc (ypgfpklxhq, 0.447) View more	-	04 Nov 2024
				Deep Repetitive Transcranial Magnetic Stimulation (Sham)+Varenicline (Deep rTMS Sham + Varenicline)	utsoejzrtg(ksgajcezoo) = avgdijjcmo ouynhwwsyc (ypgfpklxhq, 0.47) View more
NCT03557294 (VOTC, CTgov)	Phase 4	Acral Lentiginous Malignant Melanoma \| Smoking Cessation	313	1.0mg Varenicline b.i.d. (1.0mg Varenicline b.i.d.)	qbdvadbnks = evnndlrzij ceshsohhfn (pxehhewgrg, kriecmqiqe - aqfyndcjvq) View more	-	19 Sep 2024
				0.5mg Varenicline b.i.d. (0.5mg Varenicline b.i.d.)	qbdvadbnks = nkwnzetsol ceshsohhfn (pxehhewgrg, esjccqwxdg - rzhjgpkshw) View more
ASCO2024	Not Applicable	Smoking Cessation	-	varenicline (Medicare Advantage plan)	tmjrpihacl(narkubbgei) = pmoenagokp wpokyoayfc (publooxqgv ) View more	-	24 May 2024
				varenicline (Medicare standalone part D)	tmjrpihacl(narkubbgei) = ynzkqpcuqq wpokyoayfc (publooxqgv ) View more
ATS2024	Not Applicable	-	-	Varenicline	loxbejjkdl(wbktajyfke) = gxeqmvapwe fouhrosuan (lmkcgvmhkr )	-	19 May 2024
ATS2024	Not Applicable	Pulmonary Disease, Chronic Obstructive \| Behavioural disorders	-	Varenicline	svweywpbsb(esuzjdpucf) = tipszubrdh ornodxreme (oznxnnyjdt ) View more	-	19 May 2024
				Placebo	svweywpbsb(esuzjdpucf) = stcftduabx ornodxreme (oznxnnyjdt ) View more
ATS2024	Not Applicable	-	-	Varenicline	ldxpvsqieu(sehngguafe) = xlrzospbge iptwrojmls (vkqjjdkqmb ) View more	-	19 May 2024
NCT04957758 (CTgov)	Phase 2	Neurotrophic keratitis	113	OC-01 (varenicline) nasal spray 1.2 mg/ml (OC-01 (Varenicline) Nasal Spray, 1.2 mg/mL)	xlhohjimik(qnolcrkyzt) = ajtxxkjtst hdjqzstvqr (lwrfttrnmb, 0.17) View more	-	07 May 2024
				Placebo (vehicle) nasal spray (Placebo (Vehicle Control) Nasal Spray)	xlhohjimik(qnolcrkyzt) = sjqiktwuuj hdjqzstvqr (lwrfttrnmb, 0.15) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis